Navigation Links
Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary
Date:6/24/2008

tensible reason for the sale, which, as your letter to Taro's shareholders claims, is meant to enhance Taro's cash resources.

To date, Taro has neither been able to reconcile the valuation used in the proposed sale nor provide evidence that this is the best offer available.

3. No Transparent Sale Process. We find it telling that, in conjunction with the unfavorable terms of the proposed sale, Taro has failed to demonstrate a thorough and transparent sale process, including:

(i) No disclosure as to process. Taro has not explained what steps it has taken to ensure the best possible offer for Taro Ireland. To our knowledge, there was no public solicitation of bids. How has Taro publicized the sale? How many offers have been received? Has Taro retained financial or other advisors to assist in presenting Taro Ireland in the best possible light, and to evaluate any offers received?

In fact, on June 15, after we highlighted the failings of the proposed sale, you hastily invited Sun to submit a bid by June 23. While we see no reason to bid on an asset in which we hold a significant stake, this invitation -- seemingly an afterthought -- only exacerbates our concern that there is indeed no systematic process in place to ensure the best possible terms of sale.

(ii) Identity of proposed buyer. In addition to the undervaluation and risky form of consideration being proposed, we understand that one of the potential buyers has a close relationship with Taro's senior management. As communicated to you in the past, we have serious doubts as to the arm's length nature of the proposed transaction. Given the concerns we raised previously, this close relationship should, if anything, have prompted Taro to implement an unimpeachable sale process -- which Taro has resoundingly failed to demonstrate.

We are sure that we speak for all shareholders unaffiliated with the management in our quest to obtain full disclosure as to the process by which Taro
'/>"/>

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
2. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
3. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
4. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
5. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
8. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
9. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
10. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
11. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... OK (PRWEB) May 24, 2013 The ... casualties. And following its ravage, the mayor of Moore, one ... for new houses, said a report from cnn.com. Reaching out ... tornado victims complimentary Molderizer and Safe Shield to counter the ... the report published on May 22, 2013, caused 24 deaths, ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... LAGUNA HILLS, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... CA recently became the first hospital on ... site robotic technology. This new surgical option provides women ... Marc Winter , ... gynecologist and surgeon and medical director of minimally ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... Inc. (Nasdaq: LXRX ) today announced that Arthur ... will present,at the BIO InvestorForum at The Palace Hotel ... 11:00 a.m. Pacific Time. A live webcast of ... http://www.lexpharma.com . An archived version of the,webcast will ...
... GENZ ) announced today that it has ... the treatment of Hunter syndrome.,Elaprase is an enzyme ... and Genzyme is commercializing the product in Japan ... Shire. Genzyme intends,to launch Elaprase this quarter, following ...
... COHR ) today announced that, as anticipated, on ... letter indicating that,the Company is not currently in compliance ... 4350(e) and 4350(g) due to,its failure to hold an ... 30, 2007. The notice stated that the failure could,serve ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... the search for medication against Alzheimer,s disease, scientists have focused ... down Amyloid beta (A-beta). After all, it is the accumulation ... of Alzheimer,s patients. Starting point for the formation of A-beta ... the first to unravel the function of APPL the ... fruit flies. , Alessia Soldano (VIB/KU Leuven): "We have ...
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... -- (Nov. 14, 2011) -- To protect Houston and ... experts recommends building a floodgate across the Houston Ship ... on Galveston Island and the developed west side of ... coastal recreation area to sustainably use wetlands that act ...
... 14, 2011Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ... and Technology , a highly innovative, bimonthly peer-reviewed ... has the potential to significantly improve human health, ... and innovative results, essential data, cutting-edge discoveries, thorough ...
... Hull, Bristol and Frankfurt have shown that a new ... on small samples of biological proteins, particularly proteins that ... enhanced form of nuclear magnetic resonance (NMR) spectroscopy, could ... within hours, rather than weeks or months, radically speeding ...
Cached Biology News:Protecting Houston from the next big hurricane 2Protecting Houston from the next big hurricane 3New journal on disruptive science and technology launching in 2012 2New technique enables study of 'challenging' proteins 2
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: